Shares of Silence Therapeutics plc (LON:SLN – Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 535 ($7.16) and traded as high as GBX 546 ($7.31). Silence Therapeutics shares last traded at GBX 535 ($7.16), with a volume of 913,528 shares changing hands.
Silence Therapeutics Stock Performance
The firm’s fifty day simple moving average is GBX 535 and its 200 day simple moving average is GBX 535. The company has a market capitalization of £480.35 million and a price-to-earnings ratio of -11.01. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.52 and a quick ratio of 4.36.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Featured Articles
- Five stocks we like better than Silence Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- What Are Growth Stocks and Investing in Them
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What does consumer price index measure?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
